<DOC>
	<DOC>NCT00350181</DOC>
	<brief_summary>To evaluate the incidence of grade II-IV acute GVHD with sirolimus and mycophenolate mofetil GVHD prophylaxis.</brief_summary>
	<brief_title>Sirolimus and Mycophenolate Mofetil as Graft Versus Host Disease Prophylaxis in Myeloablative Matched Related Donor Hematopoietic Cell Transplant</brief_title>
	<detailed_description>To explore the novel combination of sirolimus and mycophenolate mofetil (MMF) as graft versus host disease (GVHD) prevention in HLA matched related donor blood or marrow transplantation (BMT). This study will report the toxicities associated with this drug combination and also explore possible correlations between specific blood cell types and antibody production during this therapy.</detailed_description>
	<mesh_term>Graft vs Host Disease</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Diagnoses Included: 1. Acute myelogenous leukemia (AML): Age 260 years beyond 2nd remission or relapsed/refractory disease. Age 5160 years of age, in first or subsequent remission or relapsed/refractory disease AML with multilineage dysplasia 2. Acute lymphoblastic leukemia (ALL): Age 260 years beyond 2nd remission or relapsed/refractory disease Age 5160 years in first or subsequent remission or relapsed/refractory disease 3. Chronic myelogenous leukemia (CML), beyond 2nd chronic phase or in blast crisis 4. Myelodysplastic syndrome (MDS) including patients with World Health Organization (WHO) refractory anemia with excess blasts1 (RAEB1), RAEB2 and therapyrelated MDS 5. Myeloproliferative disorders with poor long term survival including myeloid metaplasia and myelofibrosis 6. Nonhodgkin lymphoma (NHL) High risk NHL in first remission Relapsed or refractory NHL 7. Hodgkin lymphoma beyond first remission Other 1. Patients 260 years of age 2. Matched related donor identified, 6/6 HLAA, B and DRB1 3. Karnofsky performance status &gt;= 70% or Lansky performance status &gt;= 70% or patients &lt; 16 years old. 4. Willingness and ability to take oral medications in pill form during the transplantation period. 5. Informed consent 1. Prior myeloablative, allogeneic or autologous HCT. 2. HIV infection 3. Pregnant or lactating patients 4. Evidence of uncontrolled active infection 5. Renal function: serum creatinine &gt;1.5 mg/dl or 24 hour creatinine clearance &gt; 50 ml/min. 6. Hepatic function: direct bilirubin, ALT or AST &gt; 2 x upper limit of normal 7. Pulmonary function: In adults, corrected diffusing capacity (DLCO) &lt; 60% predicted and in children, room air oxygen saturation &lt;92%. 8. Cardiac function: In adults, left ventricular ejection fraction &lt; 45% and in children, shortening fraction &lt; 26%. 9. Fasting Cholesterol &gt; 300 mg/dl or Triglycerides &gt;300 gm/dl while on lipidlowering agents. 10.Patients receiving other investigational drugs unless cleared by the Principal Investigator. 11. Patients with prior malignancies except basal cell carcinoma or treated carcinoma insitu. Cancer treated with curative intent &gt; 5 years will be allowed. Cancer treated with curative intent d 5 years will not be allowed without Protocol Chair approval.</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>October 2010</verification_date>
</DOC>